These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34237097)

  • 1. CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria.
    Palacios Araya D; Palmer KL; Duerkop BA
    PLoS Pathog; 2021 Jul; 17(7):e1009672. PubMed ID: 34237097
    [No Abstract]   [Full Text] [Related]  

  • 2. Using CRISPR-Cas systems as antimicrobials.
    Bikard D; Barrangou R
    Curr Opin Microbiol; 2017 Jun; 37():155-160. PubMed ID: 28888103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CRISPR design for next-generation antimicrobials.
    Beisel CL; Gomaa AA; Barrangou R
    Genome Biol; 2014 Nov; 15(11):516. PubMed ID: 25417800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance.
    Aslam B; Rasool M; Idris A; Muzammil S; Alvi RF; Khurshid M; Rasool MH; Zhang D; Ma Z; Baloch Z
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):131. PubMed ID: 32778162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas antimicrobials: Challenges and future prospects.
    Pursey E; Sünderhauf D; Gaze WH; Westra ER; van Houte S
    PLoS Pathog; 2018 Jun; 14(6):e1006990. PubMed ID: 29902258
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria.
    Kiga K; Tan XE; Ibarra-Chávez R; Watanabe S; Aiba Y; Sato'o Y; Li FY; Sasahara T; Cui B; Kawauchi M; Boonsiri T; Thitiananpakorn K; Taki Y; Azam AH; Suzuki M; Penadés JR; Cui L
    Nat Commun; 2020 Jun; 11(1):2934. PubMed ID: 32523110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas system, antibiotic resistance and virulence in bacteria: Through a common lens.
    Roy S; Naha S; Rao A; Basu S
    Prog Mol Biol Transl Sci; 2021; 178():123-174. PubMed ID: 33685595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjugative Delivery of CRISPR-Cas9 for the Selective Depletion of Antibiotic-Resistant Enterococci.
    Rodrigues M; McBride SW; Hullahalli K; Palmer KL; Duerkop BA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31527030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted mutagenesis of Mycoplasma gallisepticum using its endogenous CRISPR/Cas system.
    Mahdizadeh S; Sansom FM; Lee SW; Browning GF; Marenda MS
    Vet Microbiol; 2020 Nov; 250():108868. PubMed ID: 33039728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plants as sources of new antimicrobials and resistance-modifying agents.
    Abreu AC; McBain AJ; Simões M
    Nat Prod Rep; 2012 Sep; 29(9):1007-21. PubMed ID: 22786554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panacea in progress: CRISPR and the future of its biological research introduction.
    Carroll M; Zhou X
    Microbiol Res; 2017 Aug; 201():63-74. PubMed ID: 28602403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis.
    Gholizadeh P; Aghazadeh M; Ghotaslou R; Rezaee MA; Pirzadeh T; Cui L; Watanabe S; Feizi H; Kadkhoda H; Kafil HS
    Ann Clin Microbiol Antimicrob; 2021 Jul; 20(1):49. PubMed ID: 34321002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CRISPR-Antibiotic Resistance Connection.
    Gilmore MS
    CRISPR J; 2019 Aug; 2():199-200. PubMed ID: 31436505
    [No Abstract]   [Full Text] [Related]  

  • 14. Nanoantibiotics: A Novel Rational Approach to Antibiotic Resistant Infections.
    Engin AB; Engin A
    Curr Drug Metab; 2019; 20(9):720-741. PubMed ID: 31385767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CRISPR-Cas systems as weapons against pathogenic bacteria].
    Bikard D; Barrangou R
    Biol Aujourdhui; 2017; 211(4):265-270. PubMed ID: 29956653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotrophs: The complexity of antibiotic-subsisting and antibiotic-resistant microorganisms.
    Woappi Y; Gabani P; Singh A; Singh OV
    Crit Rev Microbiol; 2016; 42(1):17-30. PubMed ID: 24495094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of CRISPR in evolution analysis, detecting and typing, virulence and antibiotic resistance regulation in food-borne pathogens].
    Bai Z; Wang W; Ji X; Xiao Y; Zhang S; Wang Z; Li H; Dong Q
    Sheng Wu Gong Cheng Xue Bao; 2021 Jul; 37(7):2414-2424. PubMed ID: 34327906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial resistance to antimicrobials.
    Ebrahim GJ
    J Trop Pediatr; 2010 Jun; 56(3):141-3. PubMed ID: 20504970
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptide based antimicrobials: Design strategies and therapeutic potential.
    Hazam PK; Goyal R; Ramakrishnan V
    Prog Biophys Mol Biol; 2019 Mar; 142():10-22. PubMed ID: 30125585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.